La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Quantum-Si a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Quantum-Si..

Quantum-Si (NASDAQ:QSI) Azioni, Catena delle Opzioni

Quantum-Si

Quantum-Si Inc is focused on revolutionizing the growing field of proteomics. The company's suite of technologies is powered by a first-of-its-kind semiconductor chip designed to enable single-molecule next-generation protein sequencing and genomics, and digitize proteomic research in order to advance drug discovery and diagnostics beyond DNA sequencing.

Quantum-Si Incorporated - Class A Common Stock

Quantum-Si Inc

WisdomTree U.S. Short Term Corporate Bond Fund

Pacer Metaurus Nasdaq 100 Dividend Multiplier 600 ETF

<p>Burford Capital Limited, the leading global finance and asset management firm focused on law, has noted inaccurate media reporting and subsequent market reaction to an expected court filing last night by the U.S. Department of Justice ("DOJ") in the Petersen and Eton Park matters. The filing in the U.S. District Court for the Southern District of New York restates DOJ's position on a narrow question of law in relation to enforcement of judgments. The filing pertains to one motion filed in the Petersen and Eton Park matters as part of the overall, ongoing effort to enforce the judgment against the Argentine Republic. The filing does not reflect DOJ's taking any broader position on the overall case or the enforcement campaign; indeed, DOJ has previously taken the position that pursuing Argentina in the US courts for its breach of contract in this matter was appropriate, and DOJ has not made any filing at all on the pending appeal (and the time to do so has passed). In its filing, DOJ took the view that Argentina could not be required by a U.S. court to move property presently located in Argentina into the United States so it could there be attached for creditors under New York law, which is an unsettled legal issue. The DOJ view is not binding on the court and further briefing and proceedings will ensue. The Company will provide a further update on the Petersen and Eton Park matters during today's earnings call.</p>


News

Legal

Burford Capital Highlights Inaccurate Media Reports On DOJ Court Filing In Petersen, Eton Park Cases; Filing Focuses on Legal Enforcement Issue, Not Broader Case; DOJ States Argentina's Property Cannot Be Moved To U.S. For Creditor Attachment; The DOJ View Is Not Binding On The Court And Further Briefing And Proceedings Will Ensue

<p>Tourmaline Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRML#NASDAQ">TRML</a>) reported quarterly losses of $(0.78) per share which beat the analyst consensus estimate of $(0.84) by 7.14 percent.</p>


Earnings

Guidance

TRML

Tourmaline Bio Q3 2024 GAAP EPS $(0.78) Beats $(0.84) Estimate, Cash, Cash Equivalents And Investments Of $314.4M, Providing Cash Runway Into 2027

<p>Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.</p>
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58933b2043eaaa0001698f4c/eric-coldwell">Baird analyst Eric Coldwell</a> upgraded the rating for <strong>McKesson Corporation</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>) from Neutral to Outperform and raised the price target from $531 to $688. McKesson shares closed at $549.31 on Wednesday. <a href="https://www.benzinga.com/quote/MCK/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Raymond James analyst Ric Prentiss upgraded <strong>United States Cellular Corporation</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USM#NYSE">USM</a>) from Market Perform to Outperform and announced a price target of $86. United States Cellular shares closed at $65.15 on Wednesday. <a href="https://www.benzinga.com/quote/USM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5e00b6e13513fb0001f03e9b/kristen-kluska">Cantor Fitzgerald analyst Kristen Kluska</a> upgraded the rating for <strong>Sarepta Therapeutics, Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) from Neutral to Overweight and boosted the price target from $152 to $167. Sarepta Therapeutics shares closed at $127.97 on Wednesday. <a href="https://www.benzinga.com/quote/SRPT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst Alexei Gogolev upgraded <strong>Clearwater Analytics Holdings, Inc</strong>. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CWAN#NYSE">CWAN</a>) from Neutral to Overweight and raised the price target from $23 to $33. Clearwater Analytics shares closed at $28.58 on Wednesday. <a href="https://www.benzinga.com/quote/CWAN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo analyst Steven Cahall upgraded the rating for <strong>Sinclair, Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBGI#NASDAQ">SBGI</a>) from Underweight to Equal-Weight and increased the price target from $13 to $19. Sinclair shares closed at $17.41 on Wednesday. <a href="https://www.benzinga.com/quote/SBGI/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
<p>Considering buying MCK stock? Here&#8217;s what analysts think: </p>
<p><figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="562" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07075449/image-75-1024x562.png" alt="" class="wp-image-635130" style="width:629px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07075449/image-75-1024x562.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07075449/image-75-300x165.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07075449/image-75-768x421.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07075449/image-75.png 1216w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure></p>
<p><strong>Read This Next:<a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41776764/jim-cramer-this-financial-stock-is-a-buy-likes-broadcom"> </a></strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41776764/jim-cramer-this-financial-stock-is-a-buy-likes-broadcom">Jim Cramer: This Financial Stock Is A Buy, Likes Broadcom</a></strong></li>
</ul>


Upgrades

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

CWAN

SBGI

SRPT

This McKesson Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

<p>Keefe, Bruyette &amp; Woods  analyst Paul Johnson   upgrades TriplePoint Venture Gwth (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPVG#NYSE">TPVG</a>) from Underperform to Market Perform and lowers the price target from $8 to $7.5.</p>


Price Target

TPVG

Keefe, Bruyette & Woods Upgrades TriplePoint Venture Gwth to Market Perform, Lowers Price Target to $7.5

Biotech

Health Care

General

CARM

CARISMA Therapeutics' Q3 Cash And Cash Equivalents Of $26.9M Expected To Fund The Company Into The Third Quarter Of 2025

<p>Stephens &amp; Co.  analyst Jim Salera   reiterates Papa John's International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PZZA#NASDAQ">PZZA</a>) with a Overweight and maintains $62 price target.</p>


Reiteration

PZZA

Stephens & Co. Reiterates Overweight on Papa John's International, Maintains $62 Price Target

WIIM

KVYO

Klaviyo shares are trading lower. The company reported Q3 financial results.

<p>CARISMA Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARM#NASDAQ">CARM</a>) reported quarterly losses of $(0.31) per share which missed the analyst consensus estimate of $(0.24) by 29.17 percent.  The company reported quarterly sales of $3.38 million which missed the analyst consensus estimate of $5.47 million by 38.08 percent.  This is a 11.55 percent decrease over sales of $3.83 million the same period last year.</p>


CARISMA Therapeutics Q3 2024 GAAP EPS $(0.31) Misses $(0.24) Estimate, Sales $3.38M Miss $5.47M Estimate

MRNA

Moderna shares are trading higher after the company reported better-than-expected Q3 sales results.

<p>Burford Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BUR#NYSE">BUR</a>) reported quarterly earnings of $0.61 per share which missed the analyst consensus estimate of $0.92 by 33.7 percent.  The company reported quarterly sales of $249.114 million which missed the analyst consensus estimate of $393.893 million by 36.76 percent.  This is a 32.47 percent decrease over sales of $368.873 million the same period last year.</p>


Earnings Misses

Burford Capital Q3 2024 GAAP EPS $0.61 Misses $0.92 Estimate, Sales $249.114M Miss $393.893M Estimate

<p>Chicago Atlantic Real Estate Finance, Inc<em>.</em>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REFI#NASDAQ">REFI</a>) <a href="https://www.globenewswire.com/en/news-release/2024/11/07/2976505/0/en/Chicago-Atlantic-Real-Estate-Finance-Announces-Third-Quarter-2024-Financial-Results.html">announced</a> strong third-quarter results for 2024. The company, a commercial mortgage real estate investment trust (REIT) specializing in cannabis-related assets, reported significant net income growth and expanding portfolio performance, underpinned by disciplined loan management.</p>
<h3 class="wp-block-heading"><strong>Key Financial Highlights for Q3 2024</strong></h3>
<ul>
<li><strong>Net Interest Income:</strong>&nbsp;$14.5 million, up from $13.2 million in Q2 2024 and a 9.1% increase from Q3 2023.</li>
<li><strong>Net Income:</strong>&nbsp;$11.2 million, or $0.56 per share, a 21.7% sequential increase and a 19% year-over-year increase.</li>
<li><strong>Distributable Earnings:</strong>&nbsp;$11.2 million, or $0.56 per share, reflecting a 12% quarterly increase and a 15% year-over-year rise.</li>
<li><strong>Book Value:</strong>&nbsp;$15.05 per share, up slightly from $14.92 in <a href="https://www.benzinga.com/markets/cannabis/24/08/40228072/cannabis-reit-chicago-atlantic-nets-9-2m-in-strong-q2-citing-regulatory-tailwinds">Q2 2024</a>, showing growth in shareholder equity.</li>
</ul>
<h3 class="wp-block-heading"><strong>Portfolio And Investment Activity</strong></h3>
<p>As of September 30, 2024, Chicago Atlantic's portfolio included<strong> $362.3 million in <a href="https://www.benzinga.com/markets/cannabis/24/10/41496393/chicago-atlantic-secures-bbb-rating-and-50m-loan-to-enhance-liquidity-in-cannabis-lending">loan principal </a>across 29 companies</strong>, with a real estate collateral coverage of 1.2x, slightly down from 1.3x in June. </p>
<p>The company originated $32.7 million in gross loans during Q3, including $24 million to new borrowers and $8.7 million to existing ones, with a weighted average yield to maturity of 18.3%. </p>
<p>After the quarter's close, Chicago Atlantic funded an additional $36.5 million, including a $25 million credit facility with an Illinois operator.</p>
<ul>
<li><strong><em>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. You can&#8217;t afford to miss out if you're serious about the business.</em></strong></li>
</ul>
<p>"We have managed our portfolio and its maturities very well throughout 2024 with extensions, modifications, and refinancings, while improving credit quality and loan coverage,&#8221; stated co-CEO <strong><a href="https://www.benzinga.com/markets/cannabis/24/10/41237545/exclusive-weed-companies-will-be-treated-like-normal-businesses-once-this-tax-provision-goes-awa">Peter Sack</a></strong>. &#8220;A strong pipeline in both existing and new states with adult-use legislation keeps us well-positioned for the balance of the year and into 2025."</p>
<p><strong>Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/10/41237545/exclusive-weed-companies-will-be-treated-like-normal-businesses-once-this-tax-provision-goes-awa">EXCLUSIVE: Weed Companies Will Be Treated Like Normal Businesses Once This Tax Provision Goes Away, Experts Say</a></strong></p>
<h3 class="wp-block-heading"><strong>Capital And Liquidity Management</strong></h3>
<p>During Q3, Chicago Atlantic increased its secured revolving credit facility to $110 million, with a drawdown of $54 million as of quarter-end, resulting in a leverage ratio of 18%. </p>
<p>In October, the company secured a $50 million unsecured term loan with a fixed interest rate of 9.0% and received an investment-grade BBB+ rating from Egan-Jones. This loan strengthens Chicago Atlantic's liquidity, leaving $94.5 million available under the facility and approximately $80 million in total liquidity as of early November.</p>
<p>The company also paid a quarterly dividend of $0.47 per share on October 15, reflecting its steady return to shareholders amid robust performance.</p>
<h3 class="wp-block-heading"><strong>REFI Stock Price Action</strong></h3>
<p>REFI shares closed Wednesday at <strong>$15.58</strong> per share gaining +0.33 during the trading session, which represents a 2.16% increase.</p>
<ul>
<li><strong>Read Next: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40607517/delivering-returns-as-the-cannabis-market-tanks-what-wall-st-wont-tell-you-about-ch">Delivering Returns As The Cannabis Market Tanks: What Wall St Won&#8217;t Tell You About Chicago Atlantic Real Estate&#8217;s Growth</a></strong></li>
</ul>
<p><em>COVER: AI Generated Image</em></p>


Cannabis

REFI

Chicago Atlantic Real Estate Net Income Increases 19% YoY, Expands Cannabis Loan Portfolio

<p>Vertical Research   upgrades Intl Flavors &amp; Fragrances (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IFF#NYSE">IFF</a>) from Hold to Buy and announces $109 price target.</p>


Vertical Research Upgrades Intl Flavors & Fragrances to Buy, Announces $109 Price Target

<p>HC Wainwright &amp; Co.  analyst Kevin Dede   maintains Core Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORZ#NASDAQ">CORZ</a>) with a Buy and raises the price target from $15 to $17.</p>


Core Scientific, Inc. - Class A Common Stock

CORZ

HC Wainwright & Co. Maintains Buy on Core Scientific, Raises Price Target to $17

United States Cellular shares are trading higher after the company announced an agreement with AT&T to sell a portion of its retained spectrum licenses for $1.018 billion.

Dividends

CCOI

Cogent Communications Raises Dividend From $0.985 To $0.995

PRTH

Priority Technology Holdings shares are trading higher after the company reported better-than-expected Q3 EPS and sales.

Turning Point Brands shares are trading higher after the company reported better-than-expected Q3 EPS and sales and raised its guidance.

<p><strong>Clear Channel Outdoor</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCO#NYSE">CCO</a>) released its Q3 earnings on Thursday, October 31, 2024 at 06:00 AM.</p>
<p>Here's what's important from the earnings announcement.</p>
<h3>Earnings</h3>
<p>Clear Channel Outdoor missed estimated earnings by 0.0%, reporting an EPS of $-0.06 versus an estimate of $-0.06.</p>
<p>Revenue was up $32.20 million from the same period last year.</p>
<h3>Analysis of Past Earnings</h3>
<p>The company beat on EPS by $0.01 in the last quarter, resulting in a 3.0% drop share price change the following day.</p>
<p>Here's a look at Clear Channel Outdoor's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.06</td>
<td>-0.05</td>
<td>-0.17</td>
<td>0.04</td>
<td>-0.08</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.06</td>
<td>-0.04</td>
<td>-0.17</td>
<td>0.05</td>
<td>-0.11</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>557.41M</td>
<td>562.37M</td>
<td>478.55M</td>
<td>610.14M</td>
<td>594.92M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>558.99M</td>
<td>558.54M</td>
<td>481.75M</td>
<td>632.11M</td>
<td>526.79M</td>
</tr>
</tbody>
</table>
</p>
<h3>Latest Earnings Reports from Competitors</h3>
<p>With Clear Channel Outdoor's earnings data now available, it's crucial to gauge how its competitors, including PubMatic, TechTarget, and National CineMedia, have been performing.</p>
<ul>
<li>PubMatic's earnings announcement on August 08, 2024 exceeded expectations, with an actual EPS of $0.17 compared to the market's projected EPS of $-0.02, resulting in a 950.0% increase.</li>
<li>TechTarget's earnings on August 08, 2024 exceeded market projections, revealing an EPS of $0.42 compared to the estimated EPS of $0.4, resulting in a 5.0% increase.</li>
<li>National CineMedia announced earnings on November 05, 2024, revealing results below market expectations. Despite the market's anticipation of an EPS of $-0.03, National CineMedia's actual EPS was $-0.04, resulting in a -33.33% decrease compared to expectations.</li>
</ul>
<h3>Competitors Quarterly Earnings and Stock Performance Analysis</h3>
<p>In this detailed analysis, insights are provided into the market's response to the latest earnings releases of key competitors. It highlights the expected and announced earnings per share (EPS) for each company, along with their corresponding stock prices at the close of the announcement day and the open of the following trading day.</p>
<p>
<table>
<thead>
<tr>
<th><strong>Company Name</strong></th>
<th><strong>Date</strong></th>
<th style="text-align: right;"><strong>EPS Expected</strong></th>
<th style="text-align: right;"><strong>EPS Announced</strong></th>
<th><strong>EPS Change Percent</strong></th>
<th><strong>Stock Price At Close</strong></th>
<th><strong>Stock Price at Next Day Open</strong></th>
<th><strong>Price Change Percent</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Clear Channel Outdoor</td>
<td>October 31, 2024</td>
<td style="text-align: right;">-0.06</td>
<td style="text-align: right;">-0.06</td>
<td>0.0%</td>
<td>$1.47</td>
<td>$1.48</td>
<td>0.68%</td>
</tr>
<tr>
<td>PubMatic</td>
<td>August 08, 2024</td>
<td style="text-align: right;">-0.02</td>
<td style="text-align: right;">0.17</td>
<td>950.0%</td>
<td>$19.6</td>
<td>$13.82</td>
<td>-29.49%</td>
</tr>
<tr>
<td>TechTarget</td>
<td>August 08, 2024</td>
<td style="text-align: right;">0.40</td>
<td style="text-align: right;">0.42</td>
<td>5.0%</td>
<td>$29.02</td>
<td>$28.38</td>
<td>-2.21%</td>
</tr>
<tr>
<td>National CineMedia</td>
<td>November 05, 2024</td>
<td style="text-align: right;">-0.03</td>
<td style="text-align: right;">-0.04</td>
<td>-33.33%</td>
<td>$7.3</td>
<td>$7.35</td>
<td>0.68%</td>
</tr>
</tbody>
</table>
</p>
<h3>Comparative Study: Estimated vs. Actual Peer Revenues</h3>
<p>Below is a comparison of estimated and announced revenue figures for Clear Channel Outdoor's peers. This comparison gives insights into the revenue performance of these companies, providing valuable context for understanding their financial standing within the industry.</p>
<p>
<table>
<thead>
<tr>
<th><strong>Company Name</strong></th>
<th><strong>Estimated Revenue</strong></th>
<th><strong>Announced Revenue</strong></th>
<th><strong>Revenue Surprise Percentage</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Clear Channel Outdoor</td>
<td>557.41M</td>
<td>558.99M</td>
<td>0.28%</td>
</tr>
<tr>
<td>PubMatic</td>
<td>70.12M</td>
<td>67.27M</td>
<td>-4.07%</td>
</tr>
<tr>
<td>TechTarget</td>
<td>58.08M</td>
<td>58.91M</td>
<td>1.44%</td>
</tr>
<tr>
<td>National CineMedia</td>
<td>58.02M</td>
<td>62.40M</td>
<td>7.55%</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Clear Channel Outdoor <a href="https://www.benzinga.com/quote/CCO/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Clear Channel Outdoor Q3 Earnings Assessment

MTSI

MACOM Technology Solutions shares are trading higher after the company reported Q4 EPS in line with estimates and sales that beat expectations.

EPAM

EPAM Systems shares are trading higher after the company reported better-than-expected Q3 financial results and issued FY24 guidance above estimates. Also, the company issued better-than-expected Q4 revenue guidance and Adj. EPS guidance with its midpoint above estimates.

An announcement from Quantum-Si (QSI) is now available. Quantum-Si Incorporated has welcomed Charles "Chuck" Kummeth as the new Chairperson of the ...

Quantum-Si Appoints New Chairperson with Biomedical Expertise

Quantum-Si (QSI) has shared an announcement. Quantum-Si Incorporated has released an updated corporate presentation, offering an insight into its b...

Quantum-Si Shares Corporate Update with Investors

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>In most circumstances, you should avoid extremely speculative ideas, especially those billed as cheap <a href="https://investorplace.com/stock-types/penny-stocks/">penny stocks</a>. It&rsquo;s difficult to find hard statistics regarding the odds of success in this arena, in large part because of the diversity of enterprises and industries involved. However, to put it colloquially, the odds aren&rsquo;t good at all.</p>



<p>We know this because if it the odds were favorable, everybody would bet on cheap penny stocks. But it&rsquo;s not that easy and most times, the underlying entities lose considerable value. Many simply go out of business.</p>



<p>Nevertheless, the sector will always attract new generations of speculators because of the promise of quick riches. Thanks to the typically small float along with rock-bottom pricing, one piece of good news could send shares flying. Sometimes, the target equities can pop for no reason whatsoever.</p>



<p>That&rsquo;s the allure but that&rsquo;s also the risk because let&rsquo;s face it &ndash; the opposite is true as well. If you can handle the heat, below are possibly cheap penny stocks to consider.</p>



<h2>Red Cat (RCAT)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/04/drone-war-300x169.png" alt="A drone being used by soldiers."><div>Source: Gorodenkoff / Shutterstock.com</div></div><p>I&rsquo;m starting this list of cheap penny stocks with <strong>Red Cat</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/rcat-stock-quote/"><strong>RCAT</strong></a>) primarily for its core drone business. <a href="https://finance.yahoo.com/quote/RCAT/profile/">Per its public profile</a>, Red Cat builds infrastructure to manage drone fleets. It also provides services for drones, which include empowering them to fly in confined industrial interior spaces. Most importantly for this discussion, the business carries significant military implications.</p>



<p>Fundamentally, the nature of warfare may be changing before our eyes. At first, Russia&rsquo;s invasion of Ukraine seemed like an easy affair for the belligerent nation: it&rsquo;s so much bigger than its neighbor. However, Ukrainian forces managed to better even the odds thanks to its use of drones as weapons. That caught the eye of the military industrial complex and could give RCAT stock a nice pop.</p>



<p>Interestingly, RCAT trades at 3.59X trailing-year sales. In the past year, this metric averaged about 5.3X. So, in that sense, it&rsquo;s undervalued. For fiscal 2024, experts see a mitigation of red ink to 35 cents per share. However, the big item is revenue, which could jump to $18.14 million. That&rsquo;s up 83% from last year, making RCAT one of the cheap penny stocks to consider.</p>



<h2>Innoviz (INVZ)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/12/lidar-stocks-300x169.jpg" alt="LiDAR sensors show car sensing traffic around it. LAZR"><div>Source: Shutterstock</div></div><p>Based in Israel, <strong>Innoviz</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/invz-stock-quote/"><strong>INVZ</strong></a>) falls under the consumer cyclical sector, specifically the auto parts industry. <a href="https://finance.yahoo.com/quote/INVZ/profile/">Per its corporate profile</a>, Innoviz manufactures and sells automotive-grade lidar sensors and perception software. Ultimately, the company aims to enable safe autonomous driving at scale. Currently, the company offers InnoivzOne, which is a lidar sensor for auto manufacturers and robotaxi specialists.</p>



<p>To be fair, what makes INVZ stock rather risky is that we&rsquo;re still far off from the vision of fully autonomous vehicles. However, as we&rsquo;re seeing with artificial intelligence, innovation can move at breakneck speeds. During the trailing 12 months (TTM), the company incurred a net loss of nearly $119 million. However, revenue came out to $26.92 million and is growing at a blistering pace.</p>



<p>Even with the growth, shares trade at 5.46X trailing-year sales. In the past year, however, the metric averaged over 52X. Of course, that gives you an idea of how volatile INVZ stock has been in the market. Nevertheless, analysts project that sales will hit $32.45 million by year&rsquo;s end. If so, that would imply a 55.4% leap from last year&rsquo;s tally of $20.88 million.</p>



<p>If you like big wagers, INVZ could be one of the cheap penny stocks to consider.</p>



<h2>Quantum-Si (QSI)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/07/medical-bills-1600-300x169.png" alt="Doctor or physician calculating a patients medical bills at a desk. Medical bills, health costs, health expenses."><div>Source: THICHA SATAPITANON / Shutterstock</div></div><p>Headquartered in Branford, Connecticut, <strong>Quantum-Si</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/qsi-stock-quote/"><strong>QSI</strong></a>) falls under the broader healthcare sector, specifically medical devices. <a href="https://finance.yahoo.com/quote/QSI/profile/">According to its corporate profile</a>, Quantum-Si engages in the development of single-molecule detection platforms to enable next-generation protein sequencing (or NGPS). It offers instruments, software and reagent kits for the purposes of forwarding NGPS.</p>



<p>As you might imagine, the company isn&rsquo;t yet profitable. In the past four quarters, its average loss per share came out to 16.3 cents. That said, analysts anticipated that the red ink would amount to 19.3 cents. Technically speaking, then, QSI stock enjoys an &ldquo;earnings&rdquo; surprise of 15.4%.</p>



<p>In the TTM period, Quantum-Si incurred a net loss of $91.82 million or 65 cents per share. Revenue during the cycle hit $1.28 million. However, the growth trend is incredibly robust. For fiscal 2024, covering experts believe that sales could hit $4.02 million. If so, we&rsquo;re talking an expansion of 271.5%.</p>



<p>Not only that, in the following year, sales could soar to $12.4 million. That would be up another 208.5%. If you believe in these projections, QSI could be one of the cheap penny stocks to consider.</p>



<p><strong><em>On Penny Stocks and Low-Volume Stocks:&#8239;</em></strong><em>With only the rarest exceptions,&nbsp;InvestorPlace&nbsp;does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s&nbsp;writers disclose this fact and warn readers of the risks.</em></p>



<p><strong><em>Read More: &#8239;</em></strong><a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank"><em>Penny Stocks &mdash;&nbsp;How to Profit Without Getting Scammed</em></a></p>



<p><em>On the date of publication, Josh Enomoto</em><em> did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;</em><em>The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;</em><a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank"><em>Publishing Guidelines</em></a><em>.</em><em></em></p>
<div><p>A former senior business analyst for Sony Electronics, Josh Enomoto has helped broker major contracts with Fortune Global 500 companies. Over the past several years, he has delivered unique, critical insights for the investment markets, as well as various other industries including legal, construction management, and healthcare. Tweet him at @EnomotoMedia.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
<p>The post <a href="https://investorplace.com/2024/07/3-super-cheap-penny-stocks-for-the-ultimate-speculator/">3 Super-Cheap Penny Stocks for the Ultimate Speculator</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

3 Super-Cheap Penny Stocks for the Ultimate Speculator

Quantum-Si Q2 2024 Earnings Preview

Quantum-Si GAAP EPS of -$0.16 beats by $0.03, revenue of $622M beats by $621.32M

Quantum-Si incorporated (QSI) Q2 2024 Earnings Call Transcript

Analyst Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Quantum-Si (QSI – Research Report) and keeping the price target at $...

Buy Rating Affirmed for Quantum-Si on Strong Financials and Promising Product Pipeline

Quantum-Si (QSI) has shared an announcement. Quantum-Si Incorporated has updated its corporate presentation, now available for investors and the br...

Quantum-Si Shares Updated Corporate Presentation

Quantum-Si (QSI) has shared an announcement. Grace Johnston, Ph.D. has stepped down as Chief Commercial Officer of Quantum-Si Incorporated, with he...

Quantum-Si Announces Executive Leadership Transition

Warning: QSI is at high risk of performing badly

INVZ

QSIAW

RCAT

Press Releases

Quantum-Si Announces New Executive Team Members to Accelerate the Evolution of the Company into a Leading Proteomic Tool Provider

Liberate Bio Integrates Quantum-Si's Next-Generation Protein Sequencing™ Platform to Enhance Gene Therapy Development

Quantum-Si to Host Investor & Analyst Event in New York City on November 20th, 2024

Northwestern Proteomics Center of Excellence Partners with Quantum-Si for Webinar on Advancing Proteoform Analysis with Top-Down Mass Spectrometry and Single-Molecule Sequencing

Comments

Quantum-Si

Quantum-Si (QSI) Opzioni

Quantum-Si (NASDAQ:QSI) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO